Aurinia Pharmaceuticals (AUPH) versus Kitov Pharmaceuticals Holdings (KTOV) Head to Head Comparison

Aurinia Pharmaceuticals (NASDAQ: AUPH) and Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Profitability

This table compares Aurinia Pharmaceuticals and Kitov Pharmaceuticals Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals -16,648.93% -28.61% -22.50%
Kitov Pharmaceuticals Holdings N/A N/A N/A

Analyst Ratings

This is a summary of recent recommendations for Aurinia Pharmaceuticals and Kitov Pharmaceuticals Holdings, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals 0 0 6 0 3.00
Kitov Pharmaceuticals Holdings 0 0 0 0 N/A

Aurinia Pharmaceuticals currently has a consensus target price of $12.00, suggesting a potential upside of 107.97%. Given Aurinia Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Kitov Pharmaceuticals Holdings.

Volatility and Risk

Aurinia Pharmaceuticals has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Kitov Pharmaceuticals Holdings has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500.

Insider & Institutional Ownership

27.7% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.0% of Kitov Pharmaceuticals Holdings shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Kitov Pharmaceuticals Holdings’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Aurinia Pharmaceuticals $170,000.00 2,835.45 -$23.29 million ($1.37) -4.21
Kitov Pharmaceuticals Holdings N/A N/A -$12.12 million N/A N/A

Kitov Pharmaceuticals Holdings has higher revenue, but lower earnings than Aurinia Pharmaceuticals.

Summary

Kitov Pharmaceuticals Holdings beats Aurinia Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

About Kitov Pharmaceuticals Holdings

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply